Synklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV)

  • PKA pension fund lead investment, alongside The Danish Growth Fund and Eir Ventures
  • New financing will advance clinical trials with Synklino’s drug candidate SYN002 for the treatment of cytomegalovirus (CMV)

Copenhagen, Denmark, 8 June 2022 – Synklino, an emerging biotech company developing breakthrough drugs for the treatment of chronic viral infections, has completed a Series A fundraise of EUR 29.8 million (DKK 222 million / USD 31.8 million) accelerating its development plans towards significant clinical milestones.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...